ISBN 10: 0309212804 / ISBN 13: 9780309212809
Gebraucht / Anzahl: 0
Bei weiteren Verkäufern erhältlich
Alle  Exemplare dieses Buches anzeigen

Über dieses Buch

Leider ist dieses Exemplar nicht mehr verfügbar. Wir haben Ihnen weitere Exemplare dieses Titels unten aufgelistet.

Beschreibung:

Brand New, Unread Copy in Perfect Condition. A+ Customer Service!. Buchnummer des Verkäufers

Über diesen Titel:

Bewertung (bereitgestellt von GoodReads):
0 durchschnittlich
(0 Bewertungen)

Inhaltsangabe: With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them.

A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Bibliografische Details

Zustand: New

Beste Suchergebnisse bei AbeBooks

1.

Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II
Verlag: National Academies Press (2011)
ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Anzahl: 7
Anbieter
Books2Anywhere
(Fairford, GLOS, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung National Academies Press, 2011. PAP. Buchzustand: New. New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. Buchnummer des Verkäufers CA-9780309212809

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 28,82
Währung umrechnen

In den Warenkorb

Versand: EUR 10,40
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

2.

Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II, Board on Environmental Studies and Toxicology, Institute of Medicine, Division on Earth and Life Studies, National Research Council
Verlag: National Academies Press
ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Paperback Anzahl: 5
Anbieter
THE SAINT BOOKSTORE
(Southport, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung National Academies Press. Paperback. Buchzustand: new. BRAND NEW, A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration, Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II, Board on Environmental Studies and Toxicology, Institute of Medicine, Division on Earth and Life Studies, National Research Council, With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations. Buchnummer des Verkäufers B9780309212809

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 30,97
Währung umrechnen

In den Warenkorb

Versand: EUR 6,87
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

3.

Phase II Committee on Ranking FDA Product Categories Based on Health Consequences, Board on Environmental Studies and Toxicology, Institute of Medicine
Verlag: National Academies Press, United States (2011)
ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Paperback Anzahl: 1
Anbieter
The Book Depository
(London, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung National Academies Press, United States, 2011. Paperback. Buchzustand: New. 226 x 152 mm. Language: English . Brand New Book. With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations. Buchnummer des Verkäufers AAJ9780309212809

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 33,78
Währung umrechnen

In den Warenkorb

Versand: Gratis
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

4.

Phase II Committee on Ranking FDA Product Categories Based on Health Consequences, Board on Environmental Studies and Toxicology, Institute of Medicine
Verlag: National Academies Press, United States (2011)
ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Paperback Anzahl: 1
Anbieter
The Book Depository US
(London, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung National Academies Press, United States, 2011. Paperback. Buchzustand: New. 226 x 152 mm. Language: English . Brand New Book. With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations. Buchnummer des Verkäufers AAJ9780309212809

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 38,66
Währung umrechnen

In den Warenkorb

Versand: Gratis
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

5.

ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Anzahl: > 20
Anbieter
BWB
(Valley Stream, NY, USA)
Bewertung
[?]

Buchbeschreibung Buchzustand: New. Depending on your location, this item may ship from the US or UK. Buchnummer des Verkäufers 97803092128090000000

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 38,67
Währung umrechnen

In den Warenkorb

Versand: Gratis
Innerhalb USA
Versandziele, Kosten & Dauer

6.

Phase II Committee on Ranking FDA Product Categories Based on Health Consequences/ National Research Council
Verlag: National Academies Press (2011)
ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Paperback Anzahl: 1
Anbieter
Revaluation Books
(Exeter, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung National Academies Press, 2011. Paperback. Buchzustand: Brand New. 108 pages. 8.90x5.90x0.60 inches. In Stock. Buchnummer des Verkäufers __0309212804

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 40,63
Währung umrechnen

In den Warenkorb

Versand: EUR 6,94
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

7.

National Research Council Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II
Verlag: National Academy Press
ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Anzahl: 3
Anbieter
Majestic Books
(London, ,, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung National Academy Press. Buchzustand: New. pp. 108. Buchnummer des Verkäufers 95950812

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 39,77
Währung umrechnen

In den Warenkorb

Versand: EUR 6,39
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

8.

Committee on Ranking FDA Product Categor
ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Paperback Anzahl: 1
Anbieter
Grand Eagle Retail
(Wilmington, DE, USA)
Bewertung
[?]

Buchbeschreibung 2011. Paperback. Buchzustand: New. 150mm x 15mm x 226mm. Paperback. With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every .Shipping may be from multiple locations in the US or from the UK, depending on stock availability. 192 pages. 0.454. Buchnummer des Verkäufers 9780309212809

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 44,28
Währung umrechnen

In den Warenkorb

Versand: Gratis
Innerhalb USA
Versandziele, Kosten & Dauer

9.

Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II; Board on Environmental Studies and Toxicology; Institute of Medicine; Division on Earth and Life Studies; National Research Council
Verlag: National Academies Press (2011)
ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Paperback Anzahl: 1
Anbieter
Irish Booksellers
(Rumford, ME, USA)
Bewertung
[?]

Buchbeschreibung National Academies Press, 2011. Paperback. Buchzustand: New. book. Buchnummer des Verkäufers 0309212804

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 45,28
Währung umrechnen

In den Warenkorb

Versand: Gratis
Innerhalb USA
Versandziele, Kosten & Dauer

10.

Committee on Ranking FDA Product Categor
ISBN 10: 0309212804 ISBN 13: 9780309212809
Neu Paperback Anzahl: 1
Anbieter
AussieBookSeller
(SILVERWATER, NSW, Australien)
Bewertung
[?]

Buchbeschreibung 2011. Paperback. Buchzustand: New. 150mm x 15mm x 226mm. Paperback. With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health conseq.Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. 192 pages. 0.454. Buchnummer des Verkäufers 9780309212809

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 47,04
Währung umrechnen

In den Warenkorb

Versand: EUR 25,95
Von Australien nach USA
Versandziele, Kosten & Dauer

Es gibt 2 weitere Exemplare dieses Buches

Alle Suchergebnisse ansehen